Cargando…

Correction to: An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants

Detalles Bibliográficos
Autores principales:	Wong, Dean F., Raoufinia, Arash, Bricmont, Patricia, Brašić, James R., McQuade, Robert D., Forbes, Robert A., Kikuchi, Tetsuro, Kuwabara, Hiroto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496612/ https://www.ncbi.nlm.nih.gov/pubmed/33394055 http://dx.doi.org/10.1007/s00228-020-03071-z

Ejemplares similares

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole
por: Frederiksen, Trine, et al.
Publicado: (2022)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
por: Vanover, Kimberly E., et al.
Publicado: (2018)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
por: Amada, Naoki, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Sex and hand differences in circadian wrist activity are independent from sex and hand differences in 2D:4D
por: Reuter, Camille, et al.
Publicado: (2009)

Positron Emission Tomography: A Tool for Identifying the Effects of Alcohol Dependence on the Brain
por: Wong, Dean F., et al.
Publicado: (2003)

Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy
por: Varlow, Cassis, et al.
Publicado: (2022)

Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice
por: Amada, Naoki, et al.
Publicado: (2023)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

Association between Striatal Subregions and Extrastriatal Regions in Dopamine D(1) Receptor Expression: A Positron Emission Tomography Study
por: Fujiwara, Hironobu, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
por: Lee, Daniel, et al.
Publicado: (2023)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Research Trends of Vitamin D Metabolism Gene Polymorphisms Based on a Bibliometric Investigation
por: Abouzid, Mohamed, et al.
Publicado: (2023)

Striatal Dopamine D(2)/D(3) Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users
por: Ballard, Michael E., et al.
Publicado: (2015)

Dopaminergic Modulation of Forced Running Performance in Adolescent Rats: Role of Striatal D1 and Extra-striatal D2 Dopamine Receptors
por: Toval, Angel, et al.
Publicado: (2021)

Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study
por: Oosterhof, Chris A., et al.
Publicado: (2015)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
por: Barman, Rajdip, et al.
Publicado: (2021)

Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
por: Fukuyama, Kouji, et al.
Publicado: (2022)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
por: Arai, Yusuke, et al.
Publicado: (2023)

Striatal Encephalitis in Neuropsychiatric Systemic Lupus Erythematosus
por: Nakamura, Keigo, et al.
Publicado: (2019)

Osteoarthritis of the Knee
por: McQuade, Jean
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g5ignvg47n5s7k1tjremiqee23